Cardiovascular Disease, Hypercholesterolemia
Conditions
Brief summary
Intake of whole grain cereals has been associated with reducing the risk of hyperlipidaemia and heart disease, however the mechanisms by which oats or oat fractions exert this effect is not totally clear. Furthermore, several large epidemiological studies and a number of recent meta-analyses of nutritional interventions have reported a positive association between increased whole grain intake and reduced risk of developing a range of chronic diseases. Recognising the important role of the gut microbiota in metabolism and metabolic disease risk, we examined the impact of whole grain oats on the human gut microbiota and cardio-metabolic risk factors. The main aims of this human study is to determine the effectiveness of a low GI whole grain oats breakfast cereal compared to a high GI, refined breakfast cereal to beneficially modulate gut microbiota and its metabolic output, plasma lipids, gut satiety hormones and inflammation markers in an at risk of cardio-metabolic disease population
Interventions
Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
Sponsors
Study design
Eligibility
Inclusion criteria
* Men and Women (age range 23-64 y) * BMI of 18-30kg/m2 * Fasting glucose concentration \>5.5 but \<7.5mmol/L * Total cholesterol \>5.2 but \<7.8mmol/L
Exclusion criteria
* medical history of heart disease, diabetes mellitus, cancer, pancreatitis or renal disease * use of lipid lowering drugs, systemic corticosteroids or drugs for regulating hemostasis * exposure to any investigational agent \<42 d before the study * presence of gastrointestinal disorder or use of a drug likely to alter gastrointestinal motility or nutrient absorption * history of substance misuse or alcoholism * current pregnancy, planned pregnancy, or given birth in the past 12 months * antibiotic treatment 6 weeks previous to study start date * allergy or intolerance to intervention breakfast cereals components * smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in faecal bacteria population | Changes in faecal bacteria populations upon consumption of the test and control cereals . Faecal samples were collected and analysed at 0, 42, 56, 112, 140 days |
Secondary
| Measure | Time frame |
|---|---|
| Faecal short chain fatty acids | High-performance liquid chromatography (HPLC) was performed to determine faecal SCFA concentration. Faecal samples were collected and analysed at 0, 42, 56, 112, 140 days |
| Changes in plasma lipids | Fasted plasma samples were analysed for determination of triacylglycerol (TAG), total cholesterol (TC), HDL-cholesterol, LDL-cholesterol. Blood plasma samples were collected and analysed at 0, 42, 56, 112, 140 days |
Other
| Measure | Time frame |
|---|---|
| Changes in insulin resistance, PYY and GLP-1 | Fasted plasma samples were analysed for determination of insulin resistance, PYY and GLP-1. Blood plasma samples were collected and analysed at 0, 42, 56, 112, 140 days |
| Changes in inflammatory markers | Fasted plasma samples were analysed for determination of IL-6, TNF-a while saliva samples were analysed for sIgA and faecal samples for calprotectin. Blood plasma samples and saliva and faecal samples were collected and analysed at 0, 42, 56, 112, 140 |
| Changes in dietary intake | 4-day diet diaries were collected analysed, to determine the macro and micronutrient content of the participant's diets during each intervention arm. Diet diaries were collected at were collected and analysed at 42 and 112 days. |
Countries
United Kingdom